On June 26, 2025 CDR-Life Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, reported CDR609 as its next clinical candidate. CDR609 is a novel TCE targeting LGR5, a surface antigen that presents a compelling opportunity for broad, tumor-specific therapeutic intervention in solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LGR5 is a challenging and largely underexploited target in cancer immunotherapy. Unlike most other highly cancer-specific targets, LGR5 is not HLA-restricted, allowing CDR609 to potentially reach a broad patient population. Its high tumor specificity, a critical requirement for the successful use of TCEs, and broad expression across multiple high-prevalence tumor types, including colorectal, gastric, liver and pancreatic cancers, position CDR609 as a differentiated and scalable therapeutic approach.

"CDR609 embodies the key elements of our T cell engager platform: precision, potency and safety," said Christian Leisner, Ph.D., CEO of CDR-Life. "By targeting LGR5, we’re advancing a first-in-class molecule that could unlock significant value for patients with tumors that are currently underserved by immunotherapy."

CDR609 is built on CDR-Life’s proprietary M-gager platform, which enables the development of TCEs that address highly challenging but clean tumor targets and thus designed to minimize off-tumor effects. The company plans to initiate IND-enabling studies in the second half of 2025. The M-gager format and platform are currently being validated in the clinic in the CDR404 Phase 1 program, which is recruiting patients whose tumors express the intracellular target MAGE-A4.

(Press release, CDR-Life, JUN 26, 2025, View Source [SID1234666505])

On June 26, 2025 Sprint Bioscience reported that results from its DCPS program have been published in Leukemia, a scientific journal from Nature and one of the leading publications in hematology and oncology. The study strengthens the validation of DCPS as a therapeutic target in the treatment of Acute Myeloid Leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article identifies biomarkers associated with AML subtypes that respond particularly well to DCPS inhibition and sheds light on the underlying mechanisms of action. The results show that AML cases with DNMT3a and FLT3 ITD mutations and low levels of the related protein FHIT are particularly sensitive to DCPS inhibition. This facilitates patient selection and thereby increases the likelihood of positive treatment outcomes. Previous observations have shown that DCPS inhibitors have minimal impact on healthy cells and normal blood formation, with no signs of adverse effects.

"The potential for patient stratification combined with the favourable safety profile strengthens our conviction that DCPS inhibitors could become an effective and safe treatment option for AML," says Martin Andersson, CSO at Sprint Bioscience.

AML is a difficult-to-treat form of blood cancer in which current standard therapies—primarily chemotherapy—carry severe side effects and offer limited efficacy. Relapse is also common, underscoring the need for safer and more effective treatments.

The article is a collaboration between Sprint Bioscience AB, the research groups of Dr. Julian Walfridsson and Dr. Hong Qian at Karolinska Institutet, NeoTargets AB, and BioReperia AB. The Swedish Foundation for Strategic Research has partially funded it through an industrial PhD fellowship."

(Press release, Sprint Bioscience, JUN 26, 2025, View Source [SID1234660963])

On June 26, 2025 LaNova Medicines reported that CDE has granted LM-108 (anti-CCR8 mAb) Breakthrough Therapy Designation (Press release, LaNova Medicines, JUN 26, 2025, View Source [SID1234656025]). This designation is for the treatment of patients with CCR8-positive gastric or gastroesophageal junction adenocarcinoma who have disease progression following first-line standard of care treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 26, 2025 (the "Effective Date"), Elevation Oncology, Inc. (the "Company") reported to have entered into a Mutual Release and Termination Agreement (the "Termination Agreement") with CSPC Megalith Biopharmaceutical Co., Ltd. ("CSPC"), pursuant to which that certain License Agreement, dated July 27, 2022, by and between the Company and CSPC (the "License Agreement") was terminated as of the Effective Date (Filing, 8-K, Elevation Oncology, JUN 26, 2025, View Source [SID1234654215]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the License Agreement, CSPC granted to the Company a worldwide exclusive right and license (outside of the People’s Republic of China, Hong Kong, Macau and Taiwan) under certain patents identified in the License Agreement and know-how to develop and commercialize products containing EO-3021, a Claudin 18.2 antibody-drug conjugate, in the treatment of cancer. As previously disclosed, on March 20, 2025, the Company announced its election to discontinue development of EO-3021.

Upon termination of the License Agreement, the rights and licenses granted to the Company thereunder from CSPC terminated, and all rights, title and interest in and to the licensed intellectual property under the License Agreement reverted to CSPC. The Termination Agreement includes a customary mutual release of claims and provides that no further payments shall be due between the Company and CSPC under the License Agreement.

On June 26, 2025 CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, reported that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten public offering (Press release, CorMedix, JUN 26, 2025, View Source [SID1234654157]). All of the shares to be sold in the offering will be offered by CorMedix. In addition, CorMedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RBC Capital Markets is acting as sole bookrunner for the offering.

CorMedix intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, expenses related to research and the development of product candidates, and potential strategic transactions, including acquisitions, joint ventures or collaborations, involving companies, products or assets that complement CorMedix’s business.

The securities described above are being offered by CorMedix pursuant to a shelf registration statement on Form S-3 which was initially filed by CorMedix with the Securities and Exchange Commission (the "SEC") May 6, 2024, and was declared effective by the SEC on May 22, 2024.

The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at View Source Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering, as well as copies of the final prospectus supplement, when available, may be obtained from RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of CorMedix’s prospectus supplement and prospectus forming part of the effective registration statement relating to these securities.